Compare Campbell Soup Co. (CPB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs TG Therapeutics Inc — how do they compare? Campbell Soup Co. trades at $22.63 (market cap $6.78B), while TG Therapeutics Inc trades at $50 (market cap $7.64B). The key difference: Campbell Soup Co. and TG Therapeutics Inc are close in size by market cap, and Campbell Soup Co. pays a 6.87% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CPB | TGTX | |
|---|---|---|
Market Cap | $6.78B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $59.06 |
52-Week Low | $20.00 | $26.94 |
Enterprise Value | $13.38B | $7.84B |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.61, up 0.85% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings have been mixed with Q2 2026 results pending. Valuation appears reasonable with P/E of 11.14 and P/S of 0.68. The stock offers a dividend yield around 7%, supported by ongoing product innovation including new protein soups and gluten-free options.
CPB presents a value opportunity with attractive dividend yield but faces execution risks amid margin challenges. Analyst consensus remains cautious with 58.6% hold ratings. The key catalyst is successful implementation of cost-saving initiatives and portfolio rebalancing to improve profitability. Near-term performance depends on Q2 earnings results and consumer spending trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
